Management is re-underwriting a specific asset or business at a value far above its cost, using fresh third-party marks
The model's full reasoning — Q3 2018 call → NOWe need to determine if management puts a concrete, externally-derived value on something the company already owns or controls, and conveys that this value is far above what the company paid, carries it at, or what the company's current results would imply. We need to look for a specific asset being valued, with an outside reference point (e.g., market transactions, third-party offers, etc.) that implies a value above cost or book. Scanning the transcript: The call covers financial results, product performance, pipeline updates. There is discussion of biosimilars, Repatha, Aimovig, etc. But is there any specific valuation of an asset? For example, they mention a milestone payment from Novartis related to Aimovig partnership. But that's a payment received, not a valuation of an asset they own. They talk about their pipeline, but no external valuation. They mention "we have over $3 billion remaining under our current authorization" for buybacks, but that's not valuing an asset. They discuss biosimilars as a growth driver, but no specific valuation. They mention "we are excited about the BCMA BiTE program" but no valuation. There is no mention of a specific asset being valued against an external reference point. No mention of a stake in another company, no mention of a property, no mention of a third-party offer. The only possible thing is the milestone payment from Novartis, but that's a payment for a partnership, not a valuation of an asset they own. They also mention "we received approval from the FDA" for Kyprolis, but that's not valuation. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TTI | TETRA Technologies, Inc. | Q1 2024 | 2024-05-01 | A |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| IRBT | iRobot Corporation | Q3 2021 | 2021-10-28 | D |
TTI · Q1 2024 → YESThe question is: Does management put a CONCRETE, EXTERNALLY-DERIVED VALUE ON SOMETHING THE COMPANY ALREADY OWNS OR CONTROLS, and convey that this value is far above what the company paid, carries it a...YES Management identifies a specific asset: its holdings in Standard Lithium and Kodiak Gas Services (marketable securities worth slightly over $13 million, with total marketable securities around $30 million). It grounds the value in an external reference—the recent Kodiak acquisition of CSI Compressco, which made the stake “very favorable to TETRA,” plus Kodiak’s $2.5 billion market cap and strong trading volumes that allow quick, low-pressure monetization.
GPRE · Q4 2023 → YESThe question is: Does management put a CONCRETE, EXTERNALLY-DERIVED VALUE ON SOMETHING THE COMPANY ALREADY OWNS OR CONTROLS, and convey that this value is far above what the company paid, carries it a...YES Todd Becker explicitly identifies the company's ethanol plants as the specific asset being valued. He states that a high-quality plant trades in the private market at $1.80–$2.00 per gallon (or $2–$2.50 to build from scratch), while the company's overall market cap and net debt imply a lower value for its ~950 million gallon capacity.
AFL · Q2 2023 → YESThe question is: Does management put a CONCRETE, EXTERNALLY-DERIVED VALUE ON SOMETHING THE COMPANY ALREADY OWNS OR CONTROLS, and convey that this value is far above what the company paid, carries it a...YES Management identifies the specific equity stake in Varagon Capital (a minority interest they already held) and grounds its value in the external transaction where Man Group is acquiring Varagon.